The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at ...
A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback